(Total Views: 176)
Posted On: 06/08/2021 10:01:21 AM
Post# of 46489
$ARDS is using monoclonal antibodies to counter serious infectious diseases appears to be one of the most promising strategies emerging in medicine today. I am also especially pleased to see that ARDS is currently applying this method to defending against the Covid-19 mutation variants as this remains the most serious threat from the pandemic and will likely continue for years to come.
From the company news:
*Announced the addition of a second inhaled monoclonal antibody ("mAb"
to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021.
More Info here: http://www.prnewswire.com/news-releases/aridi...89072.html
From the company news:
*Announced the addition of a second inhaled monoclonal antibody ("mAb"
to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021. More Info here: http://www.prnewswire.com/news-releases/aridi...89072.html
(0)
(0)Scroll down for more posts ▼
